The T-cell receptor is a protein complex, located on the surface of T cells. They are responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex molecules. From Wikipedia
Phase I trial results published in Nature Medicine show IMA203’s efficacy and safety in targeting PRAME-positive cancers, paving the way for larger trials.
